David A. Ostrov - Publications

Affiliations: 
University of Florida, Gainesville, Gainesville, FL, United States 
Area:
Biochemistry, Molecular Biology

82 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Zhang X, Santos R, Debevec G, Li D, Schutte R, Pham K, Liu C, Ostrov DA, Giulianotti M. Identification of small molecules by screening a mixture-based scaffold compound library for treatment of alpha-1 antitrypsin deficiency. Biochemical and Biophysical Research Communications. 527: 317-323. PMID 32446387 DOI: 10.1016/J.Bbrc.2020.04.037  0.327
2020 Brown M, Zhang W, Yan D, Kenath R, Le L, Wang H, Delitto D, Ostrov D, Robertson K, Liu C, Pham K. The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC. Plos One. 15: e0226917. PMID 31929540 DOI: 10.1371/Journal.Pone.0226917  0.311
2019 Pan RY, Chu MT, Wang CW, Lee YS, Lemonnier F, Michels AW, Schutte R, Ostrov DA, Chen CB, Phillips EJ, Mallal SA, Mockenhaupt M, Bellón T, Tassaneeyakul W, White KD, et al. Identification of drug-specific public TCR driving severe cutaneous adverse reactions. Nature Communications. 10: 3569. PMID 31395875 DOI: 10.1038/S41467-019-11396-2  0.326
2019 Vijay V, Miller R, Vue GS, Pezeshkian MB, Maywood M, Ast AM, Drusbosky LM, Pompeu Y, Salgado AD, Lipten SD, Geddes T, Blenc AM, Ge Y, Ostrov DA, Cogle CR, et al. Interleukin-8 blockade prevents activated endothelial cell mediated proliferation and chemoresistance of acute myeloid leukemia. Leukemia Research. 84: 106180. PMID 31299413 DOI: 10.1016/J.Leukres.2019.106180  0.324
2019 Zhang X, Kien P, Li D, Schutte RJ, Brantly M, Liu C, Ostrov DA. Targeting the site encoded by SERPINA1*E342K for treating alpha-1 antitrypsin deficiency-associated liver diseases. Febs Letters. PMID 31116417 DOI: 10.1002/1873-3468.13452  0.312
2019 Schutte RJ, Zhang X, An N, Ostrov DA, Vukmanović S. Molecular docking predictions of fragrance binding to HLA molecules. Contact Dermatitis. PMID 30957232 DOI: 10.1111/Cod.13283  0.309
2019 Graham WV, He W, Marchiando AM, Zha J, Singh G, Li HS, Biswas A, Ong MLDM, Jiang ZH, Choi W, Zuccola H, Wang Y, Griffith J, Wu J, Rosenberg HJ, ... ... Ostrov D, et al. Intracellular MLCK1 diversion reverses barrier loss to restore mucosal homeostasis. Nature Medicine. PMID 30936544 DOI: 10.1038/S41591-019-0393-7  0.343
2018 Ratnayake WS, Apostolatos CA, Apostolatos AH, Schutte RJ, Huynh MA, Ostrov DA, Acevedo-Duncan M. Oncogenic PKC-ι activates Vimentin during epithelial-mesenchymal transition in melanoma; a study based on PKC-ι and PKC-ζ specific inhibitors. Cell Adhesion & Migration. 1-17. PMID 29781749 DOI: 10.1080/19336918.2018.1471323  0.328
2018 Ostrov DA, Alkanani A, McDaniel KA, Case S, Baschal EE, Pyle L, Ellis S, Pöllinger B, Seidl KJ, Shah VN, Garg SK, Atkinson MA, Gottlieb PA, Michels AW. Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes. The Journal of Clinical Investigation. PMID 29438107 DOI: 10.1172/Jci97739  0.345
2017 Ratnayake WS, Apostolatos AH, Ostrov DA, Acevedo-Duncan M. Two novel atypical PKC inhibitors; ACPD and DNDA effectively mitigate cell proliferation and epithelial to mesenchymal transition of metastatic melanoma while inducing apoptosis. International Journal of Oncology. PMID 29048609 DOI: 10.3892/Ijo.2017.4131  0.309
2017 Pavlos R, McKinnon EJ, Ostrov DA, Peters B, Buus S, Koelle D, Chopra A, Schutte R, Rive C, Redwood A, Restrepo S, Bracey A, Kaever T, Myers P, Speers E, et al. Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles. Scientific Reports. 7: 8653. PMID 28819312 DOI: 10.1038/S41598-017-08876-0  0.319
2017 Yerly D, Pompeu YA, Schutte RJ, Eriksson KK, Strhyn A, Bracey AW, Buus S, Ostrov DA. Structural Elements Recognized by Abacavir-Induced T Cells. International Journal of Molecular Sciences. 18. PMID 28686208 DOI: 10.3390/Ijms18071464  0.308
2016 Sullivan K, Cramer-Morales K, McElroy DL, Ostrov DA, Haas K, Childers W, Hromas R, Skorski T. Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based Selection. Plos One. 11: e0147230. PMID 26784987 DOI: 10.1371/Journal.Pone.0147230  0.37
2016 Jayaraman S, Zhu R, Wangler NJ, Mechref Y, Abbruscato TJ, Ostrov DA, Karamyan VT. Allosteric Potentiation of Peptidase Neurolysin by Small Molecules Biophysical Journal. 110. DOI: 10.1016/J.Bpj.2015.11.2143  0.364
2015 Looney BM, Xia CQ, Concannon P, Ostrov DA, Clare-Salzler MJ. Effects of Type 1 Diabetes-Associated IFIH1 Polymorphisms on MDA5 Function and Expression. Current Diabetes Reports. 15: 96. PMID 26385483 DOI: 10.1007/S11892-015-0656-8  0.526
2015 Michels AW, Ostrov DA. New approaches for predicting T cell-mediated drug reactions: A role for inducible and potentially preventable autoimmunity. The Journal of Allergy and Clinical Immunology. 136: 252-7. PMID 26254052 DOI: 10.1016/J.Jaci.2015.06.024  0.327
2015 Pirmohamed M, Ostrov DA, Park BK. New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity. The Journal of Allergy and Clinical Immunology. 136: 236-44. PMID 26254050 DOI: 10.1016/J.Jaci.2015.06.022  0.319
2015 Metushi IG, Wriston A, Banerjee P, Gohlke BO, English AM, Lucas A, Moore C, Sidney J, Buus S, Ostrov DA, Mallal S, Phillips E, Shabanowitz J, Hunt DF, Preissner R, et al. Acyclovir Has Low but Detectable Influence on HLA-B*57:01 Specificity without Inducing Hypersensitivity. Plos One. 10: e0124878. PMID 26024233 DOI: 10.1371/Journal.Pone.0124878  0.311
2015 Goldfarb NE, Ohanessian M, Biswas S, McGee TD, Mahon BP, Ostrov DA, Garcia J, Tang Y, McKenna R, Roitberg A, Dunn BM. Defective hydrophobic sliding mechanism and active site expansion in HIV-1 protease drug resistant variant Gly48Thr/Leu89Met: mechanisms for the loss of saquinavir binding potency. Biochemistry. 54: 422-33. PMID 25513833 DOI: 10.1021/Bi501088E  0.312
2015 Zhao X, Puszyk WM, Lu Z, Ostrov DA, George TJ, Robertson KD, Liu C. Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma. Molecular Cancer Therapeutics. 14: 80-9. PMID 25344582 DOI: 10.1158/1535-7163.Mct-14-0229  0.315
2015 Sullivan K, Cramer-Morales K, McElroy DL, Ostrov D, Haas K, Nieborowska-Skorska M, Childers W, Mazin A, Hromas RA, Pomerantz R, Skorski T. Identification of a Small Molecule Inhibitor of RAD52 to Induce Synthetic Lethality in BRCA-Deficient Leukemias Blood. 126: 4434-4434. DOI: 10.1182/Blood.V126.23.4434.4434  0.35
2014 Akin D, Wang SK, Habibzadegah-Tari P, Law B, Ostrov D, Li M, Yin XM, Kim JS, Horenstein N, Dunn WA. A novel ATG4B antagonist inhibits autophagy and has a negative impact on osteosarcoma tumors. Autophagy. 10: 2021-35. PMID 25483883 DOI: 10.4161/Auto.32229  0.317
2014 Chen Z, Ruan Q, Han S, Xi L, Jiang W, Jiang H, Ostrov DA, Cai J. Discovery of structure-based small molecular inhibitor of αB-crystallin against basal-like/triple-negative breast cancer development in vitro and in vivo. Breast Cancer Research and Treatment. 145: 45-59. PMID 24710637 DOI: 10.1007/S10549-014-2940-8  0.305
2013 Leung WY, Hamazaki T, Ostrov DA, Terada N. Identification of adenine nucleotide translocase 4 inhibitors by molecular docking. Journal of Molecular Graphics & Modelling. 45: 173-9. PMID 24056384 DOI: 10.1016/J.Jmgm.2013.08.016  0.352
2013 Golubovskaya VM, Ho B, Zheng M, Magis A, Ostrov D, Morrison C, Cance WG. Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth. Bmc Cancer. 13: 342. PMID 23841915 DOI: 10.1186/1471-2407-13-342  0.313
2013 Salvador LA, Taori K, Biggs JS, Jakoncic J, Ostrov DA, Paul VJ, Luesch H. Potent elastase inhibitors from cyanobacteria: structural basis and mechanisms mediating cytoprotective and anti-inflammatory effects in bronchial epithelial cells. Journal of Medicinal Chemistry. 56: 1276-90. PMID 23350733 DOI: 10.1021/Jm3017305  0.369
2013 Golubovskaya VM, Ho B, Zheng M, Magis A, Ostrov D, Cance WG. Mitoxantrone targets the ATP-binding site of FAK, binds the FAK kinase domain and decreases FAK, Pyk-2, c-Src, and IGF-1R in vitro kinase activities. Anti-Cancer Agents in Medicinal Chemistry. 13: 546-54. PMID 22292772 DOI: 10.2174/1871520611313040003  0.373
2013 Golubovskaya VM, Palma NL, Zheng M, Ho B, Magis A, Ostrov D, Cance WG. A small-molecule inhibitor, 5'-O-tritylthymidine, targets FAK and Mdm-2 interaction, and blocks breast and colon tumorigenesis in vivo. Anti-Cancer Agents in Medicinal Chemistry. 13: 532-45. PMID 22292771 DOI: 10.2174/1871520611313040002  0.33
2013 Turner JG, Rowe TC, Ostrov D, Dawson JL, Pernazza D, Lawrence NJ, Sullivan DM. Targeting The Nuclear Export Signal In Multiple Myeloma Blood. 122: 1925-1925. DOI: 10.1182/Blood.V122.21.1925.1925  0.352
2013 Bennett RL, Ostrov DA, May WS. Abstract 5673: Novel inhibitors of the interferon-inducible, dsRNA-activated kinase PKR for myelodysplastic syndrome. Cancer Research. 73: 5673-5673. DOI: 10.1158/1538-7445.Am2013-5673  0.389
2013 Golubovskaya VM, Lebedyeva I, Ho B, Yemma M, Singh N, Arcara M, Ostrov D, Katritzky A, Cance W. Abstract A293: Novel allosteric small molecule FAK inhibitors effectively inhibit cancer cell viability and clonogenicity. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A293  0.328
2012 Pompeu YA, Stewart JD, Mallal S, Phillips E, Peters B, Ostrov DA. The structural basis of HLA-associated drug hypersensitivity syndromes. Immunological Reviews. 250: 158-66. PMID 23046128 DOI: 10.1111/J.1600-065X.2012.01163.X  0.334
2012 Ucar DA, Kurenova E, Garrett TJ, Cance WG, Nyberg C, Cox A, Massoll N, Ostrov DA, Lawrence N, Sebti SM, Zajac-Kaye M, Hochwald SN. Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth. Cell Cycle (Georgetown, Tex.). 11: 3250-9. PMID 22894899 DOI: 10.1093/Carcin/Bgr115  0.31
2012 Ostrov DA, Grant BJ, Pompeu YA, Sidney J, Harndahl M, Southwood S, Oseroff C, Lu S, Jakoncic J, de Oliveira CA, Yang L, Mei H, Shi L, Shabanowitz J, English AM, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proceedings of the National Academy of Sciences of the United States of America. 109: 9959-64. PMID 22645359 DOI: 10.1073/Pnas.1207934109  0.317
2012 Toro EJ, Zuo J, Ostrov DA, Catalfamo D, Bradaschia-Correa V, Arana-Chavez V, Caridad AR, Neubert JK, Wronski TJ, Wallet SM, Holliday LS. Enoxacin directly inhibits osteoclastogenesis without inducing apoptosis. The Journal of Biological Chemistry. 287: 17894-904. PMID 22474295 DOI: 10.1074/Jbc.M111.280511  0.305
2012 Demir A, Oguariri RM, Magis A, Ostrov DA, Imamichi T, Dunn BM. Kinetic characterization of newly discovered inhibitors of various constructs of human T-cell leukemia virus-1 (HTLV-1) protease and their effect on HTLV-1-infected cells. Antiviral Therapy. 17: 883-92. PMID 22436331 DOI: 10.3851/Imp2090  0.329
2012 Golubovskaya VM, Figel S, Ho BT, Johnson CP, Yemma M, Huang G, Zheng M, Nyberg C, Magis A, Ostrov DA, Gelman IH, Cance WG. A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo. Carcinogenesis. 33: 1004-13. PMID 22402131 DOI: 10.1093/Carcin/Bgs120  0.346
2012 Haire RN, Cannon JP, O'Driscoll ML, Ostrov DA, Mueller MG, Turner PM, Litman RT, Litman GW, Yoder JA. Genomic and functional characterization of the diverse immunoglobulin domain-containing protein (DICP) family. Genomics. 99: 282-91. PMID 22386706 DOI: 10.1016/J.Ygeno.2012.02.004  0.327
2012 Ezgimen M, Lai H, Mueller NH, Lee K, Cuny G, Ostrov DA, Padmanabhan R. Characterization of the 8-hydroxyquinoline scaffold for inhibitors of West Nile virus serine protease. Antiviral Research. 94: 18-24. PMID 22343093 DOI: 10.1016/J.Antiviral.2012.02.003  0.323
2012 Toro EJ, Ostrov DA, Wronski TJ, Holliday LS. Rational identification of enoxacin as a novel V-ATPase-directed osteoclast inhibitor. Current Protein & Peptide Science. 13: 180-91. PMID 22044158 DOI: 10.2174/138920312800493151  0.317
2012 Salvador L, Taori K, Ostrov D, Biggs J, Paul V, Luesch H. Novel elastase inhibitors from marine cyanobacteria: Structural diversity, target-bound crystal structures and cellular effects Planta Medica. 78. DOI: 10.1055/S-0032-1320292  0.346
2011 Kurenova EV, Liao J, He D, Hunt DL, Chekhau A, Hochwald SN, Ostrov DA, Cance WG. Effect of a novel FAK inhibitor targeted to the binding site of VEGFR3 on pancreatic cancer proliferation in vitro and in vivo. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 214. PMID 27985935 DOI: 10.1200/Jco.2011.29.4_Suppl.214  0.308
2011 Michels AW, Ostrov DA, Zhang L, Nakayama M, Fuse M, McDaniel K, Roep BO, Gottlieb PA, Atkinson MA, Eisenbarth GS. Structure-based selection of small molecules to alter allele-specific MHC class II antigen presentation. Journal of Immunology (Baltimore, Md. : 1950). 187: 5921-30. PMID 22043012 DOI: 10.4049/Jimmunol.1100746  0.348
2011 Kulemina LV, Ostrov DA. Prediction of off-target effects on angiotensin-converting enzyme 2. Journal of Biomolecular Screening. 16: 878-85. PMID 21859683 DOI: 10.1177/1087057111413919  0.365
2011 Pillai P, Desai S, Patel R, Sajan M, Farese R, Ostrov D, Acevedo-Duncan M. A novel PKC-ι inhibitor abrogates cell proliferation and induces apoptosis in neuroblastoma. The International Journal of Biochemistry & Cell Biology. 43: 784-94. PMID 21315177 DOI: 10.1016/J.Biocel.2011.02.002  0.319
2011 Graham WV, Magis AT, Bailey KM, Turner JR, Ostrov DA. Crystallization and preliminary X-ray analysis of the human long myosin light-chain kinase 1-specific domain IgCAM3. Acta Crystallographica. Section F, Structural Biology and Crystallization Communications. 67: 221-3. PMID 21301090 DOI: 10.1107/S1744309110050323  0.342
2011 Ucar DA, Magis A, He D, Ostrov D, Hochwald SN. Abstract 3582: Targeting the FAK amino terminus F2 subdomain to disrupt growth factor receptor protein interactions, signaling and function Cancer Research. 71: 3582-3582. DOI: 10.1158/1538-7445.Am2011-3582  0.338
2010 Cannon JP, Dishaw LJ, Haire RN, Litman RT, Ostrov DA, Litman GW. Recognition of additional roles for immunoglobulin domains in immune function. Seminars in Immunology. 22: 17-24. PMID 20004115 DOI: 10.1016/J.Smim.2009.11.006  0.33
2010 Hu Z, Li X, Ostrov D, Slayton W. Screening Small Molecule Inhibitors of VLA-5 to Block the Interaction Between Acute Lymphoblastic Leukemia with Ph+ and Their Microenvironment. Blood. 116: 1027-1027. DOI: 10.1182/Blood.V116.21.1027.1027  0.374
2010 Jaiswal AS, Banerjee S, Panda H, Bulkin CD, Izumi T, Sarkar FH, Ostrov DA, Narayan S. Abstract 692: Antitumor activity of novel structure-based chemotherapeutic agent for the intervention of colorectal cancer Cancer Research. 70: 692-692. DOI: 10.1158/1538-7445.Am10-692  0.306
2009 Jaiswal AS, Banerjee S, Panda H, Bulkin CD, Izumi T, Sarkar FH, Ostrov DA, Narayan S. A novel inhibitor of DNA polymerase beta enhances the ability of temozolomide to impair the growth of colon cancer cells. Molecular Cancer Research : McR. 7: 1973-83. PMID 19996303 DOI: 10.1158/1541-7786.Mcr-09-0309  0.303
2009 Corsino P, Horenstein N, Ostrov D, Rowe T, Law M, Barrett A, Aslanidi G, Cress WD, Law B. A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanism Journal of Biological Chemistry. 284: 29945-29955. PMID 19710018 DOI: 10.1074/Jbc.M109.055251  0.354
2009 Zheng D, Kurenova E, Ucar D, Golubovskaya V, Magis A, Ostrov D, Cance WG, Hochwald SN. Targeting of the protein interaction site between FAK and IGF-1R. Biochemical and Biophysical Research Communications. 388: 301-5. PMID 19664602 DOI: 10.1016/J.Bbrc.2009.07.156  0.327
2009 Kurenova EV, Hunt DL, He D, Magis AT, Ostrov DA, Cance WG. Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo. Journal of Medicinal Chemistry. 52: 4716-24. PMID 19610651 DOI: 10.1021/Jm900159G  0.35
2009 Hochwald SN, Nyberg C, Zheng M, Zheng D, Wood C, Massoll NA, Magis A, Ostrov D, Cance WG, Golubovskaya VM. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer. Cell Cycle (Georgetown, Tex.). 8: 2435-43. PMID 19571674 DOI: 10.4161/Cc.8.15.9145  0.317
2009 Yang M, Qiu J, Li Y, Ostrov D, Jia J, May WS. Expression of JAZ in Multiple Myeloma and Its Potential Role as A Novel Molecular Target. Blood. 114: 2862-2862. DOI: 10.1182/Blood.V114.22.2862.2862  0.361
2009 Turner JG, Rowe TC, Ostrov DA, Ciaravino EJ, Gump JL, Sullivan DM. Blocking a Topoisomerase IIα Nuclear Export Signal Sensitizes Human Multiple Myeloma Cells to Topoisomerase II Inhibitors. Blood. 114: 2850-2850. DOI: 10.1182/Blood.V114.22.2850.2850  0.371
2009 Kurenova EV, Hunt D, Ucar D, He D, Nyberg C, Hochwald S, Magis A, Ostrov D, Cance WG. Abstract C137: Pinpointing a protein‐protein interaction site of focal adhesion kinase and VEGFR‐3 suppresses cancer growth in vivo Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C137  0.358
2008 Ferreira AJ, Hernández Prada JA, Ostrov DA, Raizada MK. Cardiovascular protection by angiotensin-converting enzyme 2: a new paradigm. Future Cardiology. 4: 175-82. PMID 19804294 DOI: 10.2217/14796678.4.2.175  0.747
2008 Golubovskaya VM, Nyberg C, Zheng M, Kweh F, Magis A, Ostrov D, Cance WG. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. Journal of Medicinal Chemistry. 51: 7405-16. PMID 18989950 DOI: 10.1021/Jm800483V  0.374
2008 Sayyah J, Magis A, Ostrov DA, Allan RW, Braylan RC, Sayeski PP. Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth. Molecular Cancer Therapeutics. 7: 2308-18. PMID 18723478 DOI: 10.1158/1535-7163.Mct-08-0279  0.348
2008 Cannon JP, Haire RN, Magis AT, Eason DD, Winfrey KN, Hernandez Prada JA, Bailey KM, Jakoncic J, Litman GW, Ostrov DA. A bony fish immunological receptor of the NITR multigene family mediates allogeneic recognition. Immunity. 29: 228-37. PMID 18674935 DOI: 10.1016/J.Immuni.2008.05.018  0.772
2008 Magis AT, Bailey KM, Kurenova EV, Hernández Prada JA, Cance WG, Ostrov DA. Crystallization of the focal adhesion kinase targeting (FAT) domain in a primitive orthorhombic space group. Acta Crystallographica. Section F, Structural Biology and Crystallization Communications. 64: 564-6. PMID 18540077 DOI: 10.1107/S1744309108011421  0.755
2008 Hernández Prada JA, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y, Santos RA, Castellano RK, Lampkins AJ, Gubala V, Ostrov DA, Raizada MK. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 51: 1312-7. PMID 18391097 DOI: 10.1161/Hypertensionaha.107.108944  0.747
2008 Noorwez SM, Ostrov DA, McDowell JH, Krebs MP, Kaushal S. A high-throughput screening method for small-molecule pharmacologic chaperones of misfolded rhodopsin. Investigative Ophthalmology & Visual Science. 49: 3224-30. PMID 18378578 DOI: 10.1167/Iovs.07-1539  0.324
2008 Hernandez Prada JA, Madden SL, Ostrov DA, Hernandez MA. Molecular modeling optimization of anticoagulant pyridine derivatives. Journal of Molecular Graphics & Modelling. 26: 1365-9. PMID 18372200 DOI: 10.1016/J.Jmgm.2008.01.006  0.745
2008 Yang M, Yang GQ, Jia J, Ostrov D, May WS. JAZ “Targeting” Compounds Induce G1 Cell Cycle Arrest Followed by Cell Death in Human Leukemia Cells Blood. 112: 2658-2658. DOI: 10.1182/Blood.V112.11.2658.2658  0.378
2007 Ostrov DA, Hernández Prada JA, Haire RN, Cannon JP, Magis AT, Bailey K, Litman GW. Crystallization and X-ray diffraction analysis of a novel immune-type receptor from Ictalurus punctatus and phasing by selenium anomalous dispersion methods. Acta Crystallographica. Section F, Structural Biology and Crystallization Communications. 63: 1035-7. PMID 18084086 DOI: 10.1107/S1744309107054231  0.752
2007 Litman GW, Cannon JP, Dishaw LJ, Haire RN, Eason DD, Yoder JA, Prada JH, Ostrov DA. Immunoglobulin variable regions in molecules exhibiting characteristics of innate and adaptive immune receptors. Immunologic Research. 38: 294-304. PMID 17917037 DOI: 10.1007/S12026-007-0014-2  0.373
2007 Ostrov DA, Hernández Prada JA, Corsino PE, Finton KA, Le N, Rowe TC. Discovery of novel DNA gyrase inhibitors by high-throughput virtual screening. Antimicrobial Agents and Chemotherapy. 51: 3688-98. PMID 17682095 DOI: 10.1128/Aac.00392-07  0.764
2007 Ostrov DA, Barnes CL, Smith LE, Binns S, Brusko TM, Brown AC, Quint PS, Litherland SA, Roopenian DC, Iczkowski KA. Characterization of HKE2: An ancient antigen encoded in the major histocompatibility complex Tissue Antigens. 69: 181-188. PMID 17257322 DOI: 10.1111/J.1399-0039.2006.00730.X  0.316
2007 Godeny MD, Sayyah J, VonDerLinden D, Johns M, Ostrov DA, Caldwell-Busby J, Sayeski PP. The N-terminal SH2 domain of the tyrosine phosphatase, SHP-2, is essential for Jak2-dependent signaling via the angiotensin II type AT1 receptor. Cellular Signalling. 19: 600-9. PMID 17027227 DOI: 10.1016/J.Cellsig.2006.08.010  0.345
2007 Yang M, Jia J, Ostrov D, Qiu J, May WS. Activation of JAZ by Small Molecules in Human Leukemia Cells. Blood. 110: 2652-2652. DOI: 10.1182/Blood.V110.11.2652.2652  0.382
2006 Hernández Prada JA, Haire RN, Allaire M, Jakoncic J, Stojanoff V, Cannon JP, Litman GW, Ostrov DA. Ancient evolutionary origin of diversified variable regions demonstrated by crystal structures of an immune-type receptor in amphioxus. Nature Immunology. 7: 875-82. PMID 16799561 DOI: 10.1038/Ni1359  0.766
2006 Sayyah J, Ostrov D, Sayeski P. Identification and Characterization of a Novel Jak2 Tyrosine Kinase Inhibitor. Blood. 108: 3604-3604. DOI: 10.1182/Blood.V108.11.3604.3604  0.34
2005 Sandberg EM, Ma X, He K, Frank SJ, Ostrov DA, Sayeski PP. Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation]. Journal of Medicinal Chemistry. 48: 2526-33. PMID 15801842 DOI: 10.1021/Jm049470K  0.363
2004 Eason DD, Cannon JP, Haire RN, Rast JP, Ostrov DA, Litman GW. Mechanisms of antigen receptor evolution. Seminars in Immunology. 16: 215-26. PMID 15522620 DOI: 10.1016/J.Smim.2004.08.001  0.367
2004 Hernández Prada JA, Haire RN, Cannon JP, Litman GW, Ostrov DA. Crystallization and preliminary X-ray analysis of VCBP3 from Branchiostoma floridae. Acta Crystallographica. Section D, Biological Crystallography. 60: 2022-4. PMID 15502315 DOI: 10.1107/S0907444904020827  0.752
2004 Yoder JA, Litman RT, Mueller MG, Desai S, Dobrinski KP, Montgomery JS, Buzzeo MP, Ota T, Amemiya CT, Trede NS, Wei S, Djeu JY, Humphray S, Jekosch K, Hernandez Prada JA, ... Ostrov DA, et al. Resolution of the novel immune-type receptor gene cluster in zebrafish. Proceedings of the National Academy of Sciences of the United States of America. 101: 15706-11. PMID 15496470 DOI: 10.1073/Pnas.0405242101  0.754
2004 Huentelman MJ, Zubcevic J, Hernández Prada JA, Xiao X, Dimitrov DS, Raizada MK, Ostrov DA. Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor. Hypertension. 44: 903-6. PMID 15492138 DOI: 10.1161/01.Hyp.0000146120.29648.36  0.776
2000 Ostrov DA, Shi W, Schwartz JC, Almo SC, Nathenson SG. Structure of murine CTLA-4 and its role in modulating T cell responsiveness. Science (New York, N.Y.). 290: 816-9. PMID 11052947 DOI: 10.1126/Science.290.5492.816  0.335
2000 Melián A, Watts GF, Shamshiev A, De Libero G, Clatworthy A, Vincent M, Brenner MB, Behar S, Niazi K, Modlin RL, Almo S, Ostrov D, Nathenson SG, Porcelli SA. Molecular recognition of human CD1b antigen complexes: evidence for a common pattern of interaction with alpha beta TCRs. Journal of Immunology (Baltimore, Md. : 1950). 165: 4494-504. PMID 11035089 DOI: 10.4049/Jimmunol.165.8.4494  0.307
Show low-probability matches.